Ultragenyx Pharmaceutical Inc.
Stock Details
Is it expensive?
Trailing P/E Ratio
-3.94
Forward P/E Ratio
22.37
PEG Ratio
-0.23
-5.93
Price-to-Sales (TTM)
3.17
-10.09
-2.41
Market Cap
2.26B
2.95B
Is it profitable?
Net Profit Margin (TTM)
-90.90%
Gross Profit Margin
77.94%
Diluted EPS (TTM)
-6.10
787.67%
670.00M
Is it growing?
-2.20%
-2.36%
Is it risky?
0.38
-5.24
2.02
1.20B
Who owns it?
104.10%
3.46%
14.68%
98.32M
94.50M
Does it pay?
0.00%
0.00%
--
--
How much cash?
413.00M
-497.00M
-219.09M
4.21
- Price
- 22.97
- Percent Change
- 0.00 (0.00%)
- Previous Close
- 22.97
- Open
- 23.06
- Low
- 22.57
- High
- 23.06
52-Week Range Position (52WRP)
Cheap
Cheap
within its 1-year price range
$22.97
From 52W Low
+25.59%
From 52W High
-45.79%
Today
+0.00%
1Y Change
-38.76%
6M
$36.20
3M
$22.21
1M
$26.30
Today
$22.97
From 52W Low
+25.59%
From 52W High
-45.79%
Today
+0.00%
1Y Change
-38.76%
6M
$36.20
3M
$22.21
1M
$26.30
Today
$22.97
Cheap
within its 1-year price range
$22.97
Multi-Timeframe Analysis (MTA)
Downtrend
Most timeframes point down. One conflicting period introduces some uncertainty, but the overall direction is negative. Weaker than a Strong Downtrend, but still a bearish signal. As reflected in the Multi-Timeframe Analysis (MTA) below.
1M
-12.7%
3M
+3.4%
6M
-36.5%
1Y
-38.8%
Rate of Change (ROC)
Accelerating
Price is falling 4.7x faster than usual. As reflected in the ROC Momentum below, which compares recent monthly gain vs its 12-month average pace.
Relative Volume (RVOL)
Low Volume
Very little activity today. Thin trading can exaggerate price moves in either direction. As reflected in the Relative Volume (RVOL) below.
- Name
- Ultragenyx Pharmaceutical Inc.
- Founded
- 2010
- CEO
- Emil D. Kakkis
- Employees
- 1,294
- Fiscal Year End
- Dec 31, 2025
- Address
60 Leveroni Court
Novato
CA
94949
United States
- GICS Classification
- Health Care›Pharmaceuticals, Biotechnology & Life Sciences›Biotechnology
- Website
- www.ultragenyx.com
Indicators
Operating Cash Flow
-497.00M
Net Income
-609.00M
Backed by Cash
0.82
Earnings closely match operating cash flow. This is the healthy baseline: profits are genuine and not artificially inflated.
Most investors only look at net income, which companies can manipulate through accounting rules. Cash flow is harder to fake. A ratio above 1.0 means every dollar of profit is backed by real cash.
Indicators
Operating Cash Flow
-497.00M
Net Income
-609.00M
Backed by Cash
0.82
Earnings closely match operating cash flow. This is the healthy baseline: profits are genuine and not artificially inflated.
Most investors only look at net income, which companies can manipulate through accounting rules. Cash flow is harder to fake. A ratio above 1.0 means every dollar of profit is backed by real cash.
Stock Details
Is it expensive?
Trailing P/E Ratio
-3.94
Forward P/E Ratio
22.37
PEG Ratio
-0.23
-5.93
Price-to-Sales (TTM)
3.17
-10.09
-2.41
Market Cap
2.26B
2.95B
Is it profitable?
Net Profit Margin (TTM)
-90.90%
Gross Profit Margin
77.94%
Diluted EPS (TTM)
-6.10
787.67%
670.00M
Is it growing?
-2.20%
-2.36%
Is it risky?
0.38
-5.24
2.02
1.20B
Who owns it?
104.10%
3.46%
14.68%
98.32M
94.50M
Does it pay?
0.00%
0.00%
--
--
How much cash?
413.00M
-497.00M
-219.09M
4.21
- Price
- 22.97
- Percent Change
- 0.00 (0.00%)
- Previous Close
- 22.97
- Open
- 23.06
- Low
- 22.57
- High
- 23.06
52-Week Range Position (52WRP)
Cheap
Cheap
within its 1-year price range
$22.97
From 52W Low
+25.59%
From 52W High
-45.79%
Today
+0.00%
1Y Change
-38.76%
6M
$36.20
3M
$22.21
1M
$26.30
Today
$22.97
From 52W Low
+25.59%
From 52W High
-45.79%
Today
+0.00%
1Y Change
-38.76%
6M
$36.20
3M
$22.21
1M
$26.30
Today
$22.97
Cheap
within its 1-year price range
$22.97
Multi-Timeframe Analysis (MTA)
Downtrend
Most timeframes point down. One conflicting period introduces some uncertainty, but the overall direction is negative. Weaker than a Strong Downtrend, but still a bearish signal. As reflected in the Multi-Timeframe Analysis (MTA) below.
1M
-12.7%
3M
+3.4%
6M
-36.5%
1Y
-38.8%
Rate of Change (ROC)
Accelerating
Price is falling 4.7x faster than usual. As reflected in the ROC Momentum below, which compares recent monthly gain vs its 12-month average pace.
Relative Volume (RVOL)
Low Volume
Very little activity today. Thin trading can exaggerate price moves in either direction. As reflected in the Relative Volume (RVOL) below.
- Name
- Ultragenyx Pharmaceutical Inc.
- Founded
- 2010
- CEO
- Emil D. Kakkis
- Employees
- 1,294
- Fiscal Year End
- Dec 31, 2025
- Address
60 Leveroni Court
Novato
CA
94949
United States
- GICS Classification
- Health Care›Pharmaceuticals, Biotechnology & Life Sciences›Biotechnology
- Website
- www.ultragenyx.com